The major U.S. equity-indexes are hovering around all-time highs, and a question that frequently pops up these days, is whether some companies’ valuations might be overstretched.
However, some operate at the opposite end of the spectrum, and could yet offer investors untapped opportunities.
H.C. Wainwright analyst Ram Selvaraju points in the direction of Sorrento Therapeutics (SRNE), as one such company.
Selvaraju rates SRNE a Buy along with a $30 price target, which implies a 275% upside…
Source link
